Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Biopharma Quarter: Key Trends and Events of the Third Quarter of 2009

Published by: Decision Resources

Published: Dec. 11, 2009 - 37 Pages


Table of Contents


Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction

Events Perspective

The Genetic Testing Component of Personalized Medicine—Who Is Passing and Who Is Failing?

Genzyme: Will the King of Rare Diseases Lose Its Throne?

HPV Vaccine Developments: Gardasil vs. Cervarix

AIDS Vaccine Breakthroughs: Therapeutic and Prophylactic Possibilities

Deals Perspective

Dealmaking Initiatives in Emerging Markets

M&A Activity Energized

Notable Product Deals

Therapy-Area Deals

Technology Deals

Generics Perspective: Contracts, Controversy, Confl ict, and Competitiveness

Buying and Selling in the Industry

EU Seizes Indian Generics in Transit and Fuels Controversy

European Commission Investigates the Activities of Servier

Sanofi ’s Generic Problems Multiply

U.K. Plans for Generic Substitution Delayed

Strategy Perspective: Healthcare Reform and the Future of Pharma

The Pharma Factor

Rational Scenarios

Ramifi cations for Pharma

Winners
Losers

Decision Time
Key Strategic Issues

Scale and Size
Focus

The Bottom Line
Tables

1. HER2 Tests on the Market

2. Diagnosed Incident Cases, by Stage, of Cervical Cancer in the Major Pharmaceutical Markets, 2008 and 2013

3. Diagnosed Incident Cases of HIV Infection in the Major Pharmaceutical Markets, 2008 and 2013

4. Top Company Dealmaking Activity, Q3 2009

5. Select Deals by Therapeutic Area, Q3 2009

6. Select Stem Cell Deals, Q3 2009

7. Select Foreign Acquisitions by U.S. Generics Companies

8. Recent EMEA Generics Approvals

9. Blockbusters Facing Patent Expiry in 2010

Figures

1. Select Product/Franchise Shares of Genzyme Revenue, 2008

2. Number of Third-Quarter Deals, 2006-2009

3. Number of Deals Valued at More than $100 Million in the Third Quarter of Each Year, 2006-2009

4. Number of Deals with a Focus on Emerging Markets, 2009

5. Select Mergers and Acquisitions Valued at More than $250 Million, Q3 2009

6. Select Product Deals Valued at More than $100 Million, Q3 2009

7. Percentage of Deals by Therapeutic Area, Q3 2009

8. Percentage of Deals by Technology, Q3 2009

9. Number of Deals with a Focus on Stem Cell Technology, Q3 2009

10. Healthcare Statistics in the United States vs. Select Nations

Abstract

The rules of the game in healthcare are changing. Although U.S. healthcare reform has yet to coalesce, the European Union is cracking down on generics shipments, stirring up controversy about trade rules and counterfeit drugs, and ratcheting up its oversight of antitrust laws, launching an investigation into purported agreements between a pharma company and generics manufacturers to keep generic alternatives off the market. Companies are looking outside of their traditional strongholds and toward new opportunities in emerging geographical markets, niche diseases, and targeted approvals.

Questions Answered in This Report
  • Healthcare reform initiatives in the United States and related global moves toward cost-containment intensifi
    • ed in the third quarter. What is the outlook for U.S. healthcare reform as the issue becomes more heated? What are the implications for the generics drug business? How do these changes shape the emerging personalized medicine business model? How must pharma companies adapt to become winners in a new marketplace?
  • Dealmaking activity increased slightly in the third quarter of 2009 relative to the prior quarter. Which companies
    • were most active? What trends in dealmaking illustrate company strategies?
  • Emerging geographical markets are of great interest to makers of branded and generic pharmaceuticals. How
    • are companies gaining access to these markets? What are some of the challenges of reaching these markets?
  • The 2006 U.S. approval of a vaccine against human papillomavirus, for use in young girls with the goal of
    • warding off HPV and consequent cervical cancer, was controversial. How has that vaccine been received? What events have occurred since that initial approval? How are commercial dynamics related to this marketplace evolving?
Scope
  • Events: Genetic testing, personalized medicine, companion diagnostics, testing uptake; Genzyme's
    • troubles; HPV vaccine approvals; HIV vaccine development.
  • Dealmaking: Companies, deal values, historical comparisons, trends, technologies, products.
  • Generics: Watson expands, Wockhardt contracts; EU generic shipment seizures; legislative defi nition
    • loopholes; EC antitrust investigations; U.K. generic substitution plans.
  • Healthcare reform: Rational scenarios; winners and losers; size, scale, and focus of companies before and after reform.
Please note, the PDF e-mail from publisher version of this report is for a global site license.

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2012
2/14/2012 - 31